Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02316548 · ClinicalTrials.gov registry record · Phase 2

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

A Phase 2 study, sponsored by NRG Oncology.

Terminated
Registry status
Phase 2
Development phase
14
Enrollment target

NCT02316548 is a Phase 2 study that was terminated before completion, run by NRG Oncology. The registered enrollment target is 14 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02316548, a Phase 2 study, was terminated before completion, sponsored by NRG Oncology.

TERMINATED
Registry status
Phase 2
Development phase
14 participants
Enrollment target

Study Summary

This randomized phase II trial studies the side effects and how well postoperative intensity modulated radiotherapy works after surgery in treating patients with urothelial bladder cancer. Radiation therapy uses high energy x-rays to kill tumor cells left behind in the pelvis after surgery. It is not yet known whether surgery followed by radiotherapy is more effective than surgery alone in treating patients with urothelial bladder cancer.

Interventions

  • RADIATION Intensity-Modulated Radiation Therapy

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2015-02
Est. Completion 2017-02-01
Phase Phase 2

Sponsor

NRG Oncology

64 total trials

What the Registry Record Tells You About NCT02316548

The ClinicalTrials.gov registry entry for NCT02316548 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Intensity-Modulated Radiation Therapy is the first listed.

NCT02316548 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02316548 about?

NCT02316548 is a clinical study titled "Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer". This randomized phase II trial studies the side effects and how well postoperative intensity modulated radiotherapy works after surgery in treating patients with urothelial bladder cancer. Radiation therapy uses high energy x-rays to kill tumor cells left behind in the pelvis after surgery. It is no...

What is the current status of trial NCT02316548?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-02. Estimated completion is 2017-02-01.

What interventions are being tested in trial NCT02316548?

The interventions under investigation include: Intensity-Modulated Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT02316548?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.